CBR1
CBR1 (carbonyl reductase 1, also known as SDR21C1 or CBR) is a cytoplasmic, NADPH-dependent reductase with broad substrate specificity. It reduces quinones, prostaglandins and xenobiotics, and it takes part in glucocorticoid metabolism. Browse Assay Genie's current range of CBR1 research reagents below, or read on for the biology behind the target.
CBR1 is an NADPH-dependent reductase with broad substrate specificity. It catalyses the reduction of a wide variety of carbonyl compounds, including quinones, prostaglandins, menadione and various xenobiotics. It can convert prostaglandin E to prostaglandin F2-alpha. It can also bind glutathione, which explains its higher affinity for glutathione-conjugated substrates, and it catalyses the reduction of S-nitrosoglutathione.
The enzyme reduces the antitumour anthracyclines doxorubicin and daunorubicin to doxorubicinol and daunorubicinol, which are cardiotoxic compounds. CBR1 also contributes to glucocorticoid metabolism. In an NADPH-dependent reaction it converts cortisol or corticosterone into 20beta-dihydrocortisol or 20beta-corticosterone. These products are weak agonists of NR3C1 and NR3C2 in adipose tissue.
The CBR1 gene encodes a member of the short-chain dehydrogenase/reductase (SDR) superfamily, whose members act as NADPH-dependent oxidoreductases with wide specificity for carbonyl compounds. The protein is cytoplasmic. Alternatively spliced transcript variants have been reported for the gene. The human CBR1 gene has orthologues named Cbr1 in mouse and rat, and CBR3 is a related carbonyl reductase. Researchers studying the CBR1 protein often use it as a model for xenobiotic and drug metabolism.
CBR1 reduces doxorubicin and daunorubicin to the cardiotoxic metabolites doxorubicinol and daunorubicinol, making it relevant to studies of anthracycline action.
CBR1 reduces quinones and various xenobiotics, so it is a focus for work on how carbonyl-containing compounds are processed.
CBR1 converts cortisol and corticosterone into 20beta-reduced products that are weak agonists of NR3C1 and NR3C2 in adipose tissue.
CBR1 converts prostaglandin E to prostaglandin F2-alpha and reduces S-nitrosoglutathione, linking it to lipid mediator and glutathione-related pathways.
CBR1 is an NADPH-dependent reductase that acts on many carbonyl compounds, including quinones, prostaglandins and xenobiotics. It reduces S-nitrosoglutathione and the anthracyclines doxorubicin and daunorubicin. It also reduces cortisol and corticosterone to 20beta-reduced derivatives.
CBR1 is the HGNC symbol for carbonyl reductase 1. The aliases are SDR21C1 and CBR, and UniProt lists the protein as carbonyl reductase [NADPH] 1. The enzyme carries the EC number 1.1.1.184, and alternatively spliced transcript variants have been described.
CBR1 belongs to the short-chain dehydrogenase/reductase (SDR) superfamily. Mouse and rat both have an orthologous gene named Cbr1. Check the datasheet of any product for its validated reactivity.
A related carbonyl reductase from the same enzyme family, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P16152; product specifications from Assay Genie datasheets.